Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial

BACKGROUND: Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes. METHODS: The three-arm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferry, David, Billingham, Lucinda, Jarrett, Hugh, Dunlop, David, Woll, Penella J., Nicolson, Marianne, Shah, Riyaz, Thompson, Joyce, Spicer, James, Muthukumar, D., Skailes, Geraldine, Leonard, Pauline, Chetiyawardana, A.D., Wells, Paula, Lewanski, Conrad, Crosse, Barbara, Hill, Michelle, Gaunt, Piers, O'Byrne, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597318/
https://www.ncbi.nlm.nih.gov/pubmed/28780466
http://dx.doi.org/10.1016/j.ejca.2017.05.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597318/
https://www.ncbi.nlm.nih.gov/pubmed/28780466
http://dx.doi.org/10.1016/j.ejca.2017.05.037

Ejemplares similares